Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single centre experience

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 1968-1973

  Molife, L R ^a   Alam, S ^a   Olmos, D ^a   Puglisi, M ^a   Shah, K ^a   Fehrmann, R ^a   Trani, L ^a   Tjokrowidjaja, A ^a   De Bono, J S ^a   Banerji, U ^a   Kaye, S B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Molecularly targeted therapy; Phase I; Risk; Toxicity

Indexed keywords

MOLECULAR THERAPY AGENT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANOREXIA; ANUS TUMOR; ARTICLE; BLEEDING; BRAIN TUMOR; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHILD; DIARRHEA; EYE DISEASE; FATIGUE; FEMALE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFECTION; KIDNEY DISEASE; LUNG TUMOR; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; MORALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SARCOMA; SCHOOL CHILD; SIDE EFFECT; SKIN CARCINOMA; SKIN DISEASE; THROMBOCYTOPENIA; THYMOMA; UROGENITAL TRACT TUMOR; VASCULAR DISEASE; VOMITING;

EID: 84864944854     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds030     Document Type: Article

References (11)

1. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990; 1: 175-181.
2. Von Hoff DD, Turner J. Responses rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991; 9: 115-122.
3. Sekine I, Yamamoto N, Kunitoh H et al. Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol 2002; 13: 1300-1306.
4. Han C, Braybrooke JP, Deplanque G et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 2003; 89: 1166-1171.
5. Bachelot T, Ray-Coquard I, Catimel G et al. Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000; 11: 151-156.
6. Roberts TG, Jr, Goulart BH, Squitieri L et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292: 2130-2140.
7. Horstmann E, McCabe MS, Grochow L et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352: 895-904.
8. Arkenau HT, Olmos D, Ang JE et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008; 98: 1029-1033.
9. Janisch L, Mick R, Schilsky RL et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994; 74: 1965-1973.
10. Olmos D, A'hern RP, Marsoni S et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol 2012 Feb 21 [Epub ahead of print].
11. Postel-Vinay S, Gomez-Roca C, Molife LR et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. J Clin Oncol 2011; 29: 1728-1736.